← Lakefront Biotherapeutics NV (LKFT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Lakefront Biotherapeutics NV (LKFT)
Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-13
Conference
Pipeline
17
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Lakefront Biotherapeutics NV (LKFT) is a pharmaceutical-stage company with a market cap of approximately $1.87B trading at ~$29.47. Its lead asset GLPG3667 is in Phase 2 for Systemic Lupus Erythematosus, with additional Phase 2 assets across Ulcerative Colitis and Rheumatoid Arthritis. No upcoming catalysts are currently calendared and no recent catalysts have been reported.
The catalyst path
- 2026-12-13Conferenceimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GLPG1837 dose 1 | Phase 2 | Cystic Fibrosis |
| GLPG3667 | Phase 2 | Systemic Lupus Erythematosus |
| GLPG3970 | Phase 2 | Ulcerative Colitis |
| GLPG2737 | Phase 2 | Cystic Fibrosis |
| GLPG0974 | Phase 2 | Ulcerative Colitis |
| GLPG2222 | Phase 2 | Cystic Fibrosis |
| GLPG1837 dose 2 | Phase 2 | Cystic Fibrosis |
| GLPG1690 | Phase 2 | Systemic Sclerosis |
| GLPG1972 | Phase 2 | Osteoarthritis |
| GLPG0259 oral capsule | Phase 2 | Rheumatoid Arthritis |
| Filgotinib | Phase 3 | Rheumatoid Arthritis |
| GLPG0634 | Phase 2 | Rheumatoid Arthritis |
| GLPG1205 | Phase 2 | Ulcerative Colitis |
| Lanraplenib | Phase 2 | Sjogren's Syndrome |
| GLPG0259 (Part B) | Phase 2 | Rheumatoid Arthritis |
| GLPG1837 dose 3 | Phase 2 | Cystic Fibrosis |
| PTM filgotinib | Phase 3 | Ulcerative Colitis |
Price & technical context
3-month
+24.3%
6-month
+21.0%
12-month
+10.2%
52-wk range
$26.08–$34.64
vs 50-day MA
+12.6%
vs 200-day MA
+12.2%
Realized vol
28.0%
Max drawdown
-30.7%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LKFT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.